Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT05064189 Completed - Eye Diseases Clinical Trials

Protection of Corneal Epithelium Using Chitosan-N-acetylcysteine Eye Drops During and/or After Cataract Surgery

Start date: April 14, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to assess if treatment with Lacrimera® eye drops (Croma-Pharma GbmH, Leobendorf, Austria) during and/ or after cataract surgery has a positive effect on the ocular surface compared to control group.

NCT ID: NCT05062330 Completed - Dry Eye Clinical Trials

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Start date: August 28, 2021
Phase: Phase 3
Study type: Interventional

The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

NCT ID: NCT05056233 Completed - Cataract Clinical Trials

Systane Hydration in Subjects Undergoing Cataract Surgery

Start date: January 18, 2022
Phase: N/A
Study type: Interventional

The primary objective of this study is to demonstrate reduced corneal staining with use of Systane Hydration among subjects with dry eye disease (DED) undergoing routine cataract removal and monofocal intraocular lens (IOL) implantation.

NCT ID: NCT05056155 Completed - Dry Eye Disease Clinical Trials

Systane Complete Multi-symptom Relief

Start date: November 9, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate effective symptom relief with the use of Systane Complete among subjects with dry eye disease (DED).

NCT ID: NCT05053789 Terminated - Eye Diseases Clinical Trials

Efficacy of Different Treatment Regimens With Chitosan-N- Acetylcysteine in Moderate-to-severe Dry Eye Disease

Start date: May 12, 2021
Phase: N/A
Study type: Interventional

Aim of this pilot study is to evaluate the best treatment regime of Chitosan-N-Acetylcysteine (Lacrimera®) compared to preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).

NCT ID: NCT05049642 Terminated - Eye Diseases Clinical Trials

Effect of Chitosan-N-acetylcysteine on Subjective Pain Sensation in Corneal Abrasion

Start date: May 12, 2021
Phase: N/A
Study type: Interventional

Aim of this study is to investigate the effect of Chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria) in patients with corneal abrasion less than one third of the corneal surface on subjective pain sensation.

NCT ID: NCT05049629 Terminated - Eye Diseases Clinical Trials

Effect of Chitosan-N-Acetylcysteine on IOL-power Prior to Cataract Surgery

Start date: May 12, 2021
Phase: N/A
Study type: Interventional

Aim of this study is to evaluate the effect of treatment with Lacrimera® on calculated IOL power prior to cataract surgery and on the stability of ocular surface parameters compared to preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).

NCT ID: NCT05045508 Recruiting - Dry Eye Clinical Trials

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

Start date: August 30, 2021
Phase: Phase 3
Study type: Interventional

Evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray among subjects suffering from dry eye following photorefractive keratectomy (PRK)

NCT ID: NCT05045053 Recruiting - Corneal Disease Clinical Trials

Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

NCT ID: NCT05031806 Completed - Dry Eye Disease Clinical Trials

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

Start date: September 28, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease.